NP Genomics, Inc

Sightgene, Inc., located in Monrovia, California, is a research organization focused on advancing the understanding and treatment of primary open-angle glaucoma (POAG), a leading cause of irreversible blindness worldwide. The company aims to develop more effective clinical therapies by investigating the underlying mechanisms of glaucoma pathogenesis and exploring innovative treatment strategies. Through its research, Sightgene, Inc. utilizes unique mouse models to study the genetic factors associated with POAG, particularly the role of fibrillin-1 and transforming growth factor 2 (TGF2) in disease progression. By characterizing these mechanisms, the organization seeks to improve patient outcomes and preserve vision for those affected by this chronic condition. Generated from the website

Paradigm Immunotherapeutics, Inc., based in Monrovia, CA, focuses on developing groundbreaking technologies aimed at combating BSL 3 and 4 infectious agents, including Ebola, as well as innovative treatments for immune-mediated diseases. The company operates at the forefront of medical advancements, although the co-development of intellectual property necessitates limited public disclosure. For accredited investors, Paradigm provides access to essential materials such as a pitch deck, term sheet, team information, an executive summary, FAQs, and budget details from 2016-2018 through a designated platform. This approach underscores the company’s commitment to fostering investment in its pioneering scientific endeavors. Generated from the website